Class Cert. In Avandia MDL Undone For Lacking Stats
By Matthew Santoni · July 21, 2026, 8:00 PM EDT
The Third Circuit undid class certification for a group of health plans claiming GlaxoSmithKline deceptively marketed its diabetes drug Avandia, with a panel majority ruling Tuesday the plans needed stronger statistical...
To view the full article, register now.